Protein Design Labs Inc. agreed to buy the hospital-focused pharmaceutical firm ESP Pharma Inc. for $300 million in cash and about $175 million in stock, thereby gaining marketed products, a 75-person sales force, entry into the cardiac field - and about $14 million in ESP debt. (BioWorld Today) Read More
